| Accession |
PRJCA011967 |
| Title |
SHR-1210-III-307,A randomized,controlled, double-blind, multicenter phase III trial of efficacy and safety in squamous non-small cell lung cancer |
| Relevance |
Medical |
| Data types |
Clinical imaging metabolic biomarker gene dat
|
| Organisms |
Homo sapiens
|
| Description |
A randomized, double-blind, multicenter phase III trial of the efficacy and safety of carrelizumab plus carboplatin plus paclitaxel versus placebo plus carboplatin plus paclitaxel as first-line treatment for locally advanced or metastatic (stage IIIB-IV) squamous non-small cell lung cancer |
| Sample scope |
Multiisolate |
| Release date |
2024-09-19 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Jiangsu Hengrui Pharmaceutical Co., LTD
|
NA
|
NA
|
|
|
|
| Submitter |
Jia
Ao
Pan (jiaao.pan@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2022-09-19 |
